Emerging Oligonucleotide Therapeutics


Cambridge Healthtech Institute 第1届
新寡核苷酸治疗药
提升治疗效果的各种工具与分子实体

第15届Discovery on Target其中一环

本会议以新寡核苷酸治疗药为主题,将分享因应寡核苷酸治疗药的新分子实体开发、合成技术与传输技术改善、展延稳定性与安全性等领域的研究面及临床面成果。会期中,医药品开发相关化学、生物学、药理学研究人员将齐聚一堂,在交流知识及经验的同时,安排了能够拓展投入新医药品成分市场的人脉、并建立合作关系的活动。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Targeting HBV

· September 25 Short Course: Applications of Functional Screening Using CRISPR and RNAi

· September 26-27 Conference: CRISPR for Disease Modeling and Target Discovery

· September 27-28 Conference: Emerging Oligonucleotide Therapeutics

· September 27 Short Course: CRISPR-Based Gene Editing for Targeted Therapies

· September 28-29 Symposium: Tackling Rare Diseases


Wednesday, September 27

11:50 am Conference Registration Open

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

Development of New Oligonucleotide Platforms and Chemistries

2:45 Welcome Remarks

Tanuja Koppal, Ph.D., Conference Director, Cambridge Healthtech Institute

2:50 Chairperson's Opening Remarks

Clifford Steer, M.D., Professor of Medicine and Genetics, Cell Biology, and Development; Director, Molecular Gastroenterology Program, University of Minnesota Medical School

2:55 Chemistry Developments and Therapeutic Applications of GalNAc-siRNA Conjugates

Ivan Zlatev, Ph.D., Senior Scientist, Research, Alnylam Pharmaceuticals

3:25 RNAi Based Human Therapy for Chronic Hepatitis B Infection

Amy Lee, Ph.D., Senior Director, In Vivo Pharmacology and Macro-Molecular Discovery, Arbutus Biopharma Corp.

ARB-1467 and ARB-1740 are lipid nanoparticle-delivered RNAi therapeutics currently in Phase II MAD clinical studies. These agents are designed to inhibit viral replication and lower all viral antigens. Reducing HBV proteins, particularly HBsAg, is expected to abrogate viral suppression of immune function and facilitate reinvigoration of the host response/defense. Clinical results to date are promising, with multi-dosing resulting in stepwise, additive reduction in serum HBsAg.

3:55 Sponsored Presentation (Opportunity Available)

4:25 Refreshment Break in the Exhibit Hall with Poster Viewing

5:00 Antisense Oligonucleotides: Treating Neurological Disorders at the Level of RNA

Sarah L. DeVos, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Bradley T Hyman, Massachusetts General Hospital

Adequate therapies are lacking for neurological disorders, including Alzheimer's. Antisense oligonucleotides (ASOs) that directly target RNA of disease-associated genes may be therapeutically beneficial. Tau ASOs, for example, have rescued multiple mouse models and show target engagement in non-human primates. These and other data are moving neuro-focused ASOs from "bench to bedside", with one FDA approved ASO and several others in human clinical trials for neurodegeneration.

5:30 Oligonucleotides with Charge-Neutralizing Branched Groups on the Backbones That Enhance Cellular Uptake

David R. Tabatadze, Ph.D., President and CEO, ZATA Pharmaceuticals

Novel phosphoramidite monomers enabling the incorporation of charge-neutralizing branched groups (CNBGs) on internucleoside phosphates of oligonucleotides during the automated synthesis have been developed. BCNSs terminated with amino groups form ion pairs with neighboring phosphate groups. Such oligonucleotides possess good solubility and hybridization properties, are not involved in non-standard intramolecular aggregation, have low cytotoxicity, adequate chemical stability, improved serum stability, and display significantly enhanced cellular uptake.

6:00 Using Antisense Oligonucleotides for Treatment of Cerebellar Neurodegeneration

Stefan M. Pulst, M.D., Professor and Chair, Department of Neurology, University of Utah

Spinocerebellar Ataxia Type 2 (SCA2) is an autosomal dominant polyglutamine disease leading to death of cerebellar Purkinje cells (PCs) and other neurons. We used two SCA2 mouse models to test RNA-targeted therapies. After screening 150 antisense oligonucleotides (ASOs) in vitro, the most promising lead, ASO7, downregulated ATXN2 mRNA and protein resulting in delayed onset of SCA2 phenotypes and normalization of PC firing. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.

6:30 Close of Day

6:30 Dinner Short Course Registration

Click here for details on short courses offered.

Thursday, September 28

7:30 am Registration Open

8:00 Interactive Breakout Discussion Groups with Continental Breakfast

Grab a cup of coffee and join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

Exploring CRISPR and Other Innovative Drug Modalities

9:00 Chairperson's Remarks

Thomas D. Madden, Ph.D., President and CEO, Acuitas Therapeutics

9:05 Therapeutic Protein Expression in vivo Using Messenger RNA-Lipid Nanoparticles

Thomas D. Madden, Ph.D., President and CEO, Acuitas Therapeutics

Messenger RNA (mRNA) is an important new therapeutic modality. However mRNA is labile and requires a delivery system to access cells. New generations of lipid nanoparticle systems (LNP) allow efficient delivery and expression of mRNA via different routes of administration. Key parameters impacting potency and safety will be discussed. In addition preclinical results illustrating the application of mRNA-LNP therapeutics in a several clinical areas will be presented.

9:35 Using Single-Stranded Donor DNA for Homology Directed Repair Catalyzed by CRISPR/Cas9 Activity

Eric. B. Kmiec, Ph.D., Director, Gene Editing Institute and Senior Research Scientist, Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System

This talk will focus on utilizing the information gathered from studies on the mechanism of action and regulatory circuitry surrounding gene editing using single-stranded oligonucleotides in combination with CRISPR/Cas9. We will examine how genetic lesions often arise during the process of homology directed repair and point mutation resolution. Examples will be provided outlining the strategy for carrying out genetic surgery more precisely and how they may enable productive outcomes in the clinic.

10:05 Efficacy of U1 Adaptor Gene Silencing of the Undruggable KRAS and MYC Oncogenes in Xenograft Mice

Samuel Gunderson, Ph.D., President and Co-Founder, SilaGene Inc.

U1 Adaptors oligonucleotides (U1AOs) interfere with polyadenylation of gene-specific mRNA, causing their selective destruction inside the nucleus. U1AOs can accept extensive covalent modifications for nuclease resistance and conjugation to tumor-targeting peptides without loss of silencing activity, offering important advantages as therapeutic agents. Systemically delivered U1AO-peptide conjugates targeting KRAS and MYC lead to tumor shrinkage in xenograft mice harboring pancreatic cancer with no apparent toxicity.

10:35 Coffee Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

Oligonucleotides for Cancer Immunotherapy

11:20 RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Potentiates Immune Checkpoint Blockade

Shanthi Ganesh, Ph.D., Associate Director, Pre Clinical Oncology, Dicerna Pharmaceuticals, Inc.

Recent research implicates Wnt/β-catenin signaling as a mechanism of resistance to cancer immunotherapy. DCR-BCAT is an RNAi-based experimental drug targeting β-catenin, formulated in a tumor-selective nanoparticle. In preclinical models, systemic administration of DCR-BCAT induced rapid increases in tumor T cells and dramatically improved responses to immunotherapy agents. In this presentation, we explore the mechanism of synergistic efficacy and suggest clinical evaluation of this first-in-class RNAi agent.

11:50 SB 11285, a Novel STING Agonist for ImmunoTherapy of Cancer

R.P. (Kris) Iyer, Ph.D., Co-Founder & CSO, Spring Bank Pharmaceuticals

Immunotherapy has emerged as a transformative approach for the treatment of cancer. Evidence suggests that the activation of Stimulator of Interferon Genes (STING) pathway in tumor cells and/or immune cells induce type I Interferon production leading to apoptosis of tumor cells, as well as, induction of adaptive immune response thereby providing a powerful anti-cancer strategy. Herein, we describe the discovery and preclinical studies of SB 11285, a novel STING agonist for application in immuno-oncology.

12:20 pm Sponsored Presentation (Opportunity Available)

12:50 Session Break

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:50 Refreshment Break in the Exhibit Hall with Poster Viewing

Tackling Challenges with Delivery

2:35 Chairperson's Remarks

Dan Peer, Ph.D., Director, Laboratory of Precision NanoMedicine, Tel Aviv University

2:40 Moving from Intravenous to Subcutaneous Delivery in RNAi - Why and How

Bruce D. Given, M.D., COO, Arrowhead Pharmaceuticals

RNA interference (RNAi) occurs in the cytoplasm. RNAi triggers are routed on cell entry through endosomes, which are well equipped to metabolize RNA and to initiate host immune responses. Legacy delivery systems require mechanisms for endosomal escape and intravenous dosing. Advances in RNAi trigger chemistry and targeting allow effective knockdown without requiring active endosomal escape, without toll receptor activation and allowing subcutaneous delivery.

3:10 From Local to Systemic: Delivering Novel siRNA Therapeutics for Multiple Clinical Indications

Patrick Y. Lu, Ph.D., President & CEO, Sirnaomics, Inc.

Sirnaomics is trying to use its proprietary and optimized polypeptide-based delivery technology, to develop the novel anti-fibrotic RNAi therapeutics targeting both TGFβ1 and Cox-2 simultaneously. The initial indication is to treat skin hypertrophic scar and then extend it to liver fibrosis, such as Primary Sclerosing Cholangitis, and liver cancer, such as Cholangicarcinoma, as well as other fibrotic conditions. With INDs approved by both U.S. FDA and China FDA, we have started clinical trials in both countries. I will discuss the unique advantage of this polypeptide nanoparticle technology for efficient siRNA delivery, its pharmaceutical properties for manufacturing and its preclinical safety profile.

3:40 Session Break

3:55 A Multi-Dimensional RNA-Based Approach to Treat Genetic Disorders

Nelson Chau, Ph.D., Vice President, Drug Discovery, RaNA Therapeutics

Many genetic diseases can be treated by restoring defective gene expression. We can activate gene expression by three distinct technology platforms: 1) Targeting repressive cis-acting long noncoding RNA, 2) Enhancing stability of mRNA transcript, or 3) Supplementing in vitro transcribed mRNA. With these three different platforms, we can achieve specific gene upregulation and tailor to desired therapeutic profiles. Recent progress in the discovery and preclinical development of all three platforms will be presented.

4:25 Targeted Platform for RNA Therapeutics

Dan Peer, Ph.D., Director, Laboratory of Precision NanoMedicine, Tel Aviv University

The translation of RNA from an effective genomic tool into a novel therapeutic modality has been hindered by the difficulty to deliver RNA molecules into specific target tissues by systemic administration, especially to leukocytes. Here, I will describe some of the challenges and opportunities in modulating leukocytes response using RNA molecules and discuss adverse effects such as immuno-toxicity. In addition, I will detail the challenges of targeting lipid-based nanoparticles directly into specific cells.

4:55 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

目录下载
Catalog


Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务